Matt O'Brien
Stock Analyst at Piper Sandler
(2.19)
# 2,854
Out of 4,981 analysts
185
Total ratings
42.86%
Success rate
-5.17%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SI Shoulder Innovations | Initiates: Overweight | $18 | $15.00 | +20.00% | 1 | Aug 25, 2025 | |
| CARL Carlsmed | Initiates: Overweight | $18 | $13.74 | +31.00% | 1 | Aug 18, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $80 → $55 | $38.64 | +42.34% | 4 | Aug 7, 2025 | |
| TNDM Tandem Diabetes Care | Downgrades: Neutral | $30 → $14 | $12.79 | +9.46% | 9 | Aug 7, 2025 | |
| DXCM DexCom | Maintains: Overweight | $90 → $100 | $76.00 | +31.58% | 12 | Jul 31, 2025 | |
| CNMD CONMED | Maintains: Overweight | $80 → $68 | $54.05 | +25.81% | 13 | Jul 31, 2025 | |
| TMDX TransMedics Group | Reiterates: Overweight | $125 → $145 | $116.99 | +23.94% | 12 | Jun 4, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $100 → $80 | $59.62 | +34.18% | 12 | May 9, 2025 | |
| CVRX CVRx, Inc. | Maintains: Overweight | $20 → $12 | $8.32 | +44.23% | 9 | May 9, 2025 | |
| KIDS OrthoPediatrics | Maintains: Overweight | $40 → $30 | $20.36 | +47.38% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 → $15 | $15.63 | -4.03% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $180 → $165 | $87.47 | +88.64% | 10 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $18.40 | +46.74% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5 → $2 | $1.60 | +25.00% | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $3.60 | -2.78% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $132.50 | +5.66% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $25.34 | +2.60% | 1 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $337.94 | -8.27% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $276.40 | +19.39% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $37.66 | +32.78% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $28.08 | -43.02% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $104.34 | +10.22% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $4.38 | +173.97% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $388.79 | +8.03% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 → $140 | $104.23 | +34.32% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $94.25 | -4.51% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $16.35 | +52.91% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $1.50 | +100.00% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $2.00 | +125.00% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $104.26 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $2.63 | +470.34% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $68.46 | +58.85% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $18 | $1.53 | +1,088.24% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $24.49 | +226.66% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $4.02 | +198.51% | 1 | Jun 24, 2020 |
Shoulder Innovations
Aug 25, 2025
Initiates: Overweight
Price Target: $18
Current: $15.00
Upside: +20.00%
Carlsmed
Aug 18, 2025
Initiates: Overweight
Price Target: $18
Current: $13.74
Upside: +31.00%
PROCEPT BioRobotics
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $55
Current: $38.64
Upside: +42.34%
Tandem Diabetes Care
Aug 7, 2025
Downgrades: Neutral
Price Target: $30 → $14
Current: $12.79
Upside: +9.46%
DexCom
Jul 31, 2025
Maintains: Overweight
Price Target: $90 → $100
Current: $76.00
Upside: +31.58%
CONMED
Jul 31, 2025
Maintains: Overweight
Price Target: $80 → $68
Current: $54.05
Upside: +25.81%
TransMedics Group
Jun 4, 2025
Reiterates: Overweight
Price Target: $125 → $145
Current: $116.99
Upside: +23.94%
Globus Medical
May 9, 2025
Maintains: Overweight
Price Target: $100 → $80
Current: $59.62
Upside: +34.18%
CVRx, Inc.
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $8.32
Upside: +44.23%
OrthoPediatrics
May 8, 2025
Maintains: Overweight
Price Target: $40 → $30
Current: $20.36
Upside: +47.38%
May 2, 2025
Reiterates: Overweight
Price Target: $13 → $15
Current: $15.63
Upside: -4.03%
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $87.47
Upside: +88.64%
Mar 31, 2025
Initiates: Overweight
Price Target: $27
Current: $18.40
Upside: +46.74%
Mar 21, 2025
Downgrades: Neutral
Price Target: $5 → $2
Current: $1.60
Upside: +25.00%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $3.60
Upside: -2.78%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $132.50
Upside: +5.66%
Feb 24, 2025
Initiates: Overweight
Price Target: $26
Current: $25.34
Upside: +2.60%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $337.94
Upside: -8.27%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $276.40
Upside: +19.39%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $37.66
Upside: +32.78%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $28.08
Upside: -43.02%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $104.34
Upside: +10.22%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $4.38
Upside: +173.97%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $388.79
Upside: +8.03%
Oct 25, 2024
Reiterates: Overweight
Price Target: $125 → $140
Current: $104.23
Upside: +34.32%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $94.25
Upside: -4.51%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $16.35
Upside: +52.91%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $1.50
Upside: +100.00%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $2.00
Upside: +125.00%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $104.26
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $2.63
Upside: +470.34%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $68.46
Upside: +58.85%
Jan 29, 2021
Downgrades: Neutral
Price Target: $25 → $18
Current: $1.53
Upside: +1,088.24%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $24.49
Upside: +226.66%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $4.02
Upside: +198.51%